Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens

2009167 citationsJournal Articlebronze Open Access

Authors

Good health and well-being

Published in: Annals of Oncology

Volume 20, Issue 6, pp. 1026-1031

Field-Weighted Citation Impact: 12.55